6/25/2025

Source: SeekingAlpha

6/24/2025

NeoGenomics’ first quarter results saw revenue growth, but sales came in below market expectations, leading to a significant negative market reaction. Management attributed the quarter’s performance to strong clinical test volume growth and increased adoption of next-generation sequencing (NGS) products, partially offset by continued headwinds in the non-clinical pharma segment. CEO Tony Zook described the quarter as confirming existing strengths, highlighting, “The NGS growth above market…was c

Source: Yahoo

6/24/2025

FORT MYERS, Fla., June 24, 2025--NeoGenomics announced the appointment of Marjorie Green to its Board of Directors, effective June 19, 2025.

Source: Yahoo

6/24/2025

NeoGenomics, Inc. announced the appointment of Marjorie Green to its Board of Directors, effective June 19, 2025. Dr. Green is currently Senior Vice President and Head of Oncology, Global Clinical...

Source: Finnhub

6/17/2025

NEW YORK, June 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zeo Energy Corp.  .  Such investors are advised to contact Danielle Peyton at...

Source: Finnhub

6/17/2025

Natera, Inc. shows strong revenue growth with Medicare-backed Signatera but faces litigation risks and valuation challenges. Click for my NTRA update.

Source: SeekingAlpha

6/16/2025

While some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth. A high cash burn rate without a strong balance sheet can leave investors exposed to significant downside.

Source: Yahoo

6/11/2025

Source: SeekingAlpha

6/11/2025

Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure.

Source: Yahoo

6/2/2025

As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the testing & diagnostics services industry, including Quest (NYSE:DGX) and its peers.

Source: Yahoo

5/30/2025

Source: SeekingAlpha

5/30/2025

Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many thrive during risk-on environments, many also struggle to maintain investor confidence when the ride gets bumpy.

Source: Yahoo

5/28/2025

FORT MYERS, Fla., May 28, 2025--NeoGenomics will debut its PanTracer Family and unveil the Paletrra platform at ASCO 2025, advancing precision oncology diagnostics.

Source: Yahoo

5/28/2025

Equities struggled in the first quarter as the Trump administration proposed significant, broad-based tariffs as the cornerstone of its economic policy.

Source: SeekingAlpha

5/28/2025

NeoGenomics, Inc. will debut its PanTracer? Family, a comprehensive suite of genomic profiling tests for advanced solid tumors, at the 2025 American Society of Clinical Oncology Annual Meeting in...

Source: Finnhub

5/28/2025

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the testing & diagnostics services industry, including Guardant Health (NASDAQ:GH) and its peers.

Source: Yahoo

5/23/2025

The CDx assay is intended to detect individuals who may benefit from targeted therapies such as Emrelis.

Source: Yahoo

5/22/2025

FORT MYERS, Fla., May 22, 2025--NeoGenomics announced the commercial launch of c-MET CDx for NSCLC, its c-MET companion diagnostic immunohistochemistry (IHC) assay.

Source: Yahoo

5/22/2025

NeoGenomics, Inc. announced the commercial launch of c-MET CDx for NSCLC, its c-MET companion diagnostic immunohistochemistry assay. The test is now available to oncologists and pathologists...

Source: Finnhub

5/21/2025

A number of stocks fell in the afternoon session after the major pulled back (Nasdaq -1.3%, S&P 500 - 1.4%) as Treasury yields rose, reflecting market anxiety over a draft federal budget that could worsen the already wide US fiscal deficit.

Source: Yahoo